Prof Arun Azad
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
520 Scholarly works
10 Projects
HIGHLIGHTS
2026
Journal article
Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
DOI: 10.1007/s10928-026-10038-72026
Journal article
Germline CDK12 variants in aggressive prostate cancer.
DOI: 10.1158/2159-8290.CD-26-00842026
Journal article
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.
DOI: 10.1158/1078-0432.CCR-25-40012026
Journal article
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.
DOI: 10.1158/1078-0432.CCR-26-08712023
Research grants (ARC, NHMRC, MRFF)
Optimising Radiopharmaceutical Therapy to Improve Clinical Outcomes in Advanced Prostate Cancer
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2018
Research Grant
Vca Clinical Research Fellowship
RECENT SCHOLARLY WORKS
2026
Journal article
TALAPRO-3: Talazoparib (TALA) enzalutamide (ENZA) compared with placebo (PBO) ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.
DOI: 10.1200/jco.2026.44.17_suppl.lba50072026
Journal article
Phase I/II study to evaluate AZD9750, a novel androgen receptor proteolysis-targeting chimera, alone and in combination with other anticancer agents in patients with metastatic prostate cancer (ANDROMEDA).
DOI: 10.1200/jco.2026.44.16_suppl.tps51462026
Journal article
Germline genetic correlates in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus non-steroidal anti-androgen (NSAA) or enzalutamide (ENZA): Correlative study of ENZAMET (ANZUP 1304).
DOI: 10.1200/jco.2026.44.16_suppl.50992026
Journal article
Validation of prostate-specific antigen (PSA) decline among the Latin American subgroup of LIBERTAS: A phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC).
DOI: 10.1200/jco.2026.44.16_suppl.50212026
Journal article
Cognition of apalutamide ADT treatment responders versus non-responders.
DOI: 10.1200/JCO.2026.44.16_suppl.50852026
Journal article
An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).
DOI: 10.1200/jco.2026.44.16_suppl.108
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Understanding Biomarkers of Response and Resistance to 177-Lutetium-Psma (LuPSMA) in Metastatic Castrate-Resistant Prostate Cancer
2023
Research grants (other domestic)
Using Liquid Biopsies to Optimise Prostate Cancer Radionuclide Therapy